C4 Therapeutics (CCCC) PT Raised to $7 at Barclays Feb 26, 2026 12:14PM
TD Cowen Reiterates Buy Rating on C4 Therapeutics (CCCC) Feb 26, 2026 10:56AM
C4 Therapeutics (CCCC) PT Raised to $30 at Brookline Capital Markets Feb 23, 2026 11:58AM
C4 Therapeutics sets cemsidomide trial timelines through 2028 Jan 14, 2026 07:00AM
TD Cowen Starts C4 Therapeutics (CCCC) at Buy Dec 2, 2025 05:36AM


Nov 21, 2025 04:06PM C4 Therapeutics Inc. (CCCC) files $400M mixed shelf
Nov 6, 2025 08:15AM C4 Therapeutics, Inc. (CCCC) Misses Q3 EPS by 3c
Oct 16, 2025 07:08AM C4 Therapeutics prices $125 million stock offering
Sep 23, 2025 04:25AM C4 Therapeutics (CCCC) PT Raised to $10 at Wells Fargo
Sep 17, 2025 04:33AM Barclays Reiterates Overweight Rating on C4 Therapeutics (CCCC)
Sep 15, 2025 06:05AM Stephens Upgrades C4 Therapeutics (CCCC) to Overweight
Sep 4, 2025 05:42AM Guggenheim Starts C4 Therapeutics (CCCC) at Buy
Aug 7, 2025 09:33AM C4 Therapeutics, Inc. (CCCC) Tops Q2 EPS by 3c
May 7, 2025 04:18PM C4 Therapeutics, Inc. (CCCC) Tops Q1 EPS by 9c
Jan 14, 2025 07:00AM C4 Therapeutics Inc. (CCCC) Announces 2025 Milestones Across Clinical Portfolio of Degrader Medicines Pursuing Targets of High Unmet Need in Oncology
Dec 9, 2024 08:41AM C4 Therapeutics (CCCC) Presents Cemsidomide Phase 1 Data at the American Society for Hematology
Nov 20, 2024 07:02AM C4 Therapeutics (CCCC) Appoints Accomplished Oncology Executive Steve Hoerter to Board of Directors
Oct 31, 2024 08:03AM C4 Therapeutics, Inc. (CCCC) Tops Q3 EPS by 3c
Oct 15, 2024 04:03PM C4 Therapeutics Inc. (CCCC) Appoints Paige Mahaney as Chief Scientific Officer, Stewart Fisher Retires
Sep 19, 2024 11:45AM BMO Capital Reiterates Outperform Rating on C4 Therapeutics (CCCC)
Sep 13, 2024 10:00AM C4 Therapeutics (CCCC) Presents Monotherapy Data Demonstrating Proof of Mechanism and Early Evidence of Proof of Concept From Ongoing CFT1946 Phase 1 Trial
Sep 10, 2024 07:00AM C4 Therapeutics (CCCC) Announces Delivery of Second Development Candidate to Biogen
Sep 9, 2024 11:54AM Stifel on C4 Therapeutics (CCCC): 'we still think more context is needed for it to be a stock catalyst'
Sep 9, 2024 08:28AM BMO Capital Reiterates Outperform Rating on C4 Therapeutics (CCCC)
Sep 3, 2024 07:03AM C4 Therapeutics Inc. (CCCC) Appoints Stephen Fawell to its Board
Aug 20, 2024 07:45AM BMO Capital Reiterates Outperform Rating on C4 Therapeutics (CCCC)
Aug 1, 2024 08:47AM C4 Therapeutics, Inc. (CCCC) Reports In-Line Q2 EPS
Jun 10, 2024 06:01AM C4 Therapeutics (CCCC) Appoints Ron Cooper as Board Chair